Company
BioVie Inc
NASDAQ:BIVI
BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer’s disease, Parkinson’s disease and long COVID) and advanced liver disease. In neurodegenerative disease, the company’s drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-κB, and the associated neuroinflammation and insulin resistance but not ERK and NFκB homeostatic functions (e.g., insulin signaling and neuron growth and survival).
58 stories · page 3 of 3
BioVie aims to treat Parkinson’s and Alzheimer’s by focusing on inflammation
“BioVie is one of only a small handful of companies even considering inflammation as the primary target for reducing symptoms in those two diseases,” BioVie CEO Cuong Do said